Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brian Lippman

Physician Assistant, Medical Clearwater, FL Physician Assistant

NPI 1942297973 CMS profile 10557526

1840 N Highland Ave, Clearwater, FL 33755

Open in the dashboard

General payments

$17,177

845 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Lippman of Clearwater, FL is reported in the CMS Open Payments database as having received $17,177 across 845 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,241 162
2024 General $3,450 166
2023 General $2,892 154
2022 General $3,014 171
2021 General $4,581 192

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Lippman
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Brian Lippman were reported at $3,241. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Brian Lippman Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,581 $156 $41–$563 $132
2022 $3,014 $185 $55–$649 $149
2023 $2,892 $199 $58–$717 $160
2024 $3,450 $206 $62–$740 $164
2025 $3,241 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,503 129 payments
  2. AbbVie, Inc. $2,253 114 payments
  3. Lilly USA, LLC $1,565 80 payments
  4. Biohaven Pharmaceuticals, Inc. $1,034 11 payments
  5. Pfizer Inc. $1,013 56 payments
  6. AstraZeneca Pharmaceuticals LP $992 43 payments
  7. Amgen Inc. $958 55 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $760 35 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $570 23 payments
  10. Antares Pharma, Inc. $463 27 payments
  11. Other $5,066 272 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,250 841 payments
  2. Consulting Fee $800 1 payment
  3. Education $128 3 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $1,785 105 payments
  2. Ozempic $1,640 103 payments
  3. NURTEC ODT Primary Care $1,159 21 payments
  4. UBRELVY $1,096 52 payments
  5. MOUNJARO $889 41 payments
  6. NURTEC ODT Pain $772 41 payments
  7. Kerendia $760 35 payments
  8. QULIPTA $642 31 payments
  9. FARXIGA $565 26 payments
  10. Wegovy $552 16 payments
  11. Other $12,624 690 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 103 drugs

Part D claims

3,932

Median for Physician Assistant: 241

Drug cost

$587,892

Median for Physician Assistant: $4,110

Branded share of claims

25.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 62 $89,490
Humira Adalimumab Brand 13 $88,550
Farxiga Dapagliflozin Propanediol Brand 57 $60,174
Jardiance Empagliflozin Brand 35 $52,596
Mounjaro Tirzepatide Brand 33 $47,505
Trulicity Dulaglutide Brand 20 $32,833
Linzess Linaclotide Brand 32 $23,578
Xarelto Rivaroxaban Brand 22 $23,051
Myrbetriq Mirabegron Brand 27 $20,327
Eliquis Apixaban Brand 22 $19,226

The 10 drugs with the highest cost, of 103 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$264 — —
JARDIANCE
$255 35 —
UBRELVY
$176 — —
EVENITY
$162 — —
MOUNJARO
$155 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

845 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record